Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Morphosys Ag ADR (MOR)

Morphosys Ag ADR (MOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
MorphoSys AG Reports Second Quarter 2019 Financial Results

MorphoSys AG Reports Second Quarter 2019 Financial Results

MOR : 31.40 (+1.72%)
NVS : 90.12 (+1.17%)
MorphoSys Discloses Biomarker to Stratify Patient Population in B-MIND Study of Tafasitamab plus Bendamustine in r/r DLBCL

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / August 6, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced specifications of the biomarker that was implemented in...

MOR : 31.40 (+1.72%)
MorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines Agency

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 6, 2019 / MorphoSys AG (FSE:MOR) (Prime Standard Segment:MDAX) (Prime Standard Segment:TecDAX) (NASDAQ:MOR) today announced its intention to submit a Marketing...

MOR : 31.40 (+1.72%)
Invitation to MorphoSys Q2 2019 Conference Call on August 7, 2019

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; Nasdaq: MOR) will publish its first six months' 2019 results on

MOR : 31.40 (+1.72%)
MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology

PLANEGG, MUNICH and HALLE (SAALE), GERMANY / ACCESSWIRE / July 8, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) and Vivoryon Therapeutics AG (VVY) today announced that...

MOR : 31.40 (+1.72%)
MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 3, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that its licensing partner GSK reported in a press...

MOR : 31.40 (+1.72%)
Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 3, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that its licensing partner GSK reported in a press...

MOR : 31.40 (+1.72%)
CORRECTION: Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer

Correction of a release disseminated on June 24, 2019. Correction of an inside information acc. to Article 17 MAR of the Regulation (EU). This release clarifies Dr. Kress's years of experience.

MOR : 31.40 (+1.72%)
MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 24, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) announced that its Supervisory Board has today appointed Jean-Paul...

MOR : 31.40 (+1.72%)
MorphoSys AG Reports Outcome of Annual General Meeting 2019

All Resolutions Proposed by the Company's Management Approved

MOR : 31.40 (+1.72%)
MorphoSys AG: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 16, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR):

MOR : 31.40 (+1.72%)
MorphoSys AG: Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 16, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today announced results from the primary analysis (cut-off date November...

MOR : 31.40 (+1.72%)
MorphoSys AG to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 8, 2019 / MorphoSys AG (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 2:00 PM Eastern Time.

MOR : 31.40 (+1.72%)
MorphoSys AG Reports First Quarter 2019 Results

MOR : 31.40 (+1.72%)
NVS : 90.12 (+1.17%)
Invitation to MorphoSys Q1 2019 Conference Call on May 8, 2019

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; Nasdaq: MOR) will publish its first three months' 2019 results on

MOR : 31.40 (+1.72%)
MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma

PLANEGG/MUNICH, GERMANY and SHANGHAI, CHINA / ACCESSWIRE / April 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based clinical...

MOR : 31.40 (+1.72%)
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients

Mechelen, Belgium and Planegg/Munich, Germany; 23 April 2019; 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) and Novartis Pharma...

MOR : 31.40 (+1.72%)
GLPG : 169.54 (+1.62%)
MorphoSys Nominates New Candidate for Supervisory Board

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 10, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that it has published its agenda for the Company's ordinary...

MOR : 31.40 (+1.72%)
MorphoSys to Present at Upcoming Investor Conferences

MUNICH, GERMANY / ACCESSWIRE / April 9, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conferences:

MOR : 31.40 (+1.72%)
Dr. Sarah Fakih joins MorphoSys as Head of Corporate Communications and Investor Relations

PLANEGG/MUNICH GERMANY / ACCESSWIRE / April 1, 2019 / Dr. Sarah Fakih joined MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) as Vice President and Head of Corporate Communications...

MOR : 31.40 (+1.72%)
QGEN : 34.80 (+1.84%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
AIZ +0.95 , WELL +0.38 , SBAC +0.37 , CCI +0.66 , SO +0.26
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar